医学联络官-南京
广州燃石医学检验所有限公司
- 公司规模:1000-5000人
- 公司性质:民营公司
- 公司行业:制药/生物工程
职位信息
- 发布日期:2021-01-11
- 工作地点:南京
- 招聘人数:1人
- 工作经验:1年经验
- 学历要求:硕士
- 职位月薪:15-25万/年
- 职位类别:生物工程/生物制药
职位描述
职责描述:
1、建立区域 KOL和讲者库,制定发展计划,定期进行学术拜访和沟通;
2、搜集产品相关资料和文献,追踪分析国内外研究进展,了解领域进展及趋势,结合区域特点制定区域医学策略以及医学活动计划;
3、了解竞争产品,并和MA(医学顾问)及时交流 独立或协助召开学术会议(包括专家咨询会以及教育会议),咨询客户意见或建议,并向客户传递正确的前沿学术信息;
4、为区域产品推广策略的制定、销售故事的梳理、患者画像的确定以及客户群体的划分提供专业支持;
5、为销售部新员工提供专业培训,并定期组织销售同事进行新进展知识学习;
6、定期与所负责区域销售部门进行沟通,及时了解需求及竞争情况,帮助解决在日常工作中遇到的学术需求或反对意见,共同合作达成产品目标;
7、必要时,帮助解读检测结果解读报告,确保检测结果客观、正确的解读,并参与反对意见的处理、检测报告的模板的定稿以及升级,与销售一起拜访临床客户,协助搜集并分析规划开展临床科室会,执行学术推广活动;
8、帮助销售部同事进行讲者管理。
9、科研项目方案的制定,沟通,跟进项目进展,汇报项目结果
任职要求:
1. 生物、药学、医学相关专业,硕士或硕士以上学历,临床医学背景优先
2. 1年以上相关工作经验,有产品经理、医学联络官、报告解读经验者优先;
3. 有较好的文献解读和归纳总结能力;
4. 具备较强的社交技能和市场敏感性,有较强的学习能力和创新精神;
5. 优秀的客户服务意识和团队合作精神,跨部门沟通能力强,极好的协调能力和团队合作能力;
6. 能适应短期出差
职能类别:生物工程/生物制药
公司介绍
关于燃石医学
燃石医学(纳斯达克代码:BNR)成立于2014年,公司使命为“用科学守护生命之光”,专注于为肿瘤精准医疗提供具有临床价值的二代基因测序(NGS)。公司业务及研发方向主要覆盖:1)基于NGS的肿瘤患病人群检测,6年间,燃石累计检测样本超过18.5万例,在中国市场份额领跑行业;2)基于NGS的癌症早检,目前已经进入临床验证阶段。
燃石医学于2018年7月率先获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒,在体外诊断领域具有里程碑式意义。实验室获得广东省临检中心颁发的 “高通量测序实验室”技术审核,以及得美国CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品,推动肿瘤精准医疗领域的发展。
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
In July 2018, Burning Rock received the first approval for a tumor NGS kit by the National Medical Products Administration (NMPA), which is a significant milestone in the field of in vitro diagnosis in China. Burning Rock’s laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification. The company continues to be committed to the development of innovative and reliable NGS testing products and promoting the development of precision medicine in oncology.
燃石医学(纳斯达克代码:BNR)成立于2014年,公司使命为“用科学守护生命之光”,专注于为肿瘤精准医疗提供具有临床价值的二代基因测序(NGS)。公司业务及研发方向主要覆盖:1)基于NGS的肿瘤患病人群检测,6年间,燃石累计检测样本超过18.5万例,在中国市场份额领跑行业;2)基于NGS的癌症早检,目前已经进入临床验证阶段。
燃石医学于2018年7月率先获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒,在体外诊断领域具有里程碑式意义。实验室获得广东省临检中心颁发的 “高通量测序实验室”技术审核,以及得美国CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品,推动肿瘤精准医疗领域的发展。
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
In July 2018, Burning Rock received the first approval for a tumor NGS kit by the National Medical Products Administration (NMPA), which is a significant milestone in the field of in vitro diagnosis in China. Burning Rock’s laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification. The company continues to be committed to the development of innovative and reliable NGS testing products and promoting the development of precision medicine in oncology.
联系方式
- Email:simin.huang@brbiotech.com
- 公司地址:广州国际生物岛星岛环北路5号(燃石医学)
- 电话:17710099363